# Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

> **NCT04279379** · PHASE2 · UNKNOWN · sponsor: **Beijing Tongren Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Extranodal NK/T-cell Lymphoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT04279379
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04279379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04279379, "Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04279379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*